Abbott Declares 383rd Consecutive Quarterly Dividend
Get Alerts ABT Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.5%
Revenue Growth %: +9.8%
Join SI Premium – FREE
ABBOTT PARK, Ill., Sept. 12, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.
This marks the 383rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2019, to shareholders of record at the close of business on Oct. 15, 2019.
Abbott has increased its dividend payout for 47 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
View original content:http://www.prnewswire.com/news-releases/abbott-declares-383rd-consecutive-quarterly-dividend-300917277.html
SOURCE Abbott
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 49NORTH RELEASES GLOBAL PROCEDURE DESIGNER, A PROVEN INSTRUMENT FLIGHT PROCEDURE DESIGN SOLUTION REFRESHED FOR COMPLIANCE WITH LATEST REGULATIONS
- Xthings and ULTRALOQ to Showcase Dealer-Ready Smart Access Solutions at ALOA 2026
- Hartwig Medical Foundation and Ultima Genomics Expand Collaboration to Advance Whole-Genome Sequencing in Oncology Care
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, Dividend, Dividend AristocratsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share